- Research Article
2
- 10.4049/jimmunol.204.supp.243.22
High-dimensional profiling of tumor-infiltrating CD4+T cells in Human cancer: Are they all tumor-specific?
- May 01, 2020
- The Journal of Immunology
- Shamin Li + 6 more +6
Tumor-specific T cells act as major actors in underpinning effective immune checkpoint-blockade therapies in cancer, but most of the studies focus on CD8+ tumor-infiltrating lymphocytes (TILs). Although roles of CD4+ T cells and especially Tregs in cancer have been established, the basis for their phenotypic heterogeneity in human tumor infiltrates is not well determined. Here we profile ex-vivounexpanded CD4+ TILs in human lung and colorectal cancer using single-cell and mass-cytometry analysis. Surprisingly, up to 80% of CD4+ TILs are composed of non-Treg cells (FoxP3−). Non-Treg CD4+ TILs are highly heterogeneous and consist of different populations of effector (CD45RO+), cytotoxic (Granzyme B+), senescent (CD57+) and exhausted cells at different levels (PD-1+/++, CTLA-4+/−, TIGIT+, CD39+/−). Recently, we showed that the surface marker CD39 can accurately discriminate between bystander (CD39−) and tumor-specific (CD39+) CD8+ TILs. Across all tumors tested, more than 90% of Tregs cells expressed CD39. However, frequencies of CD39+ among non-Treg CD4+ TILs varied dramatically from 0% to 90% and strongly correlated (r2=0.8) with the frequency of CD39+CD8+ TILs in our cohort of patients. These observations suggest the presence of bystander CD4+ TILs and a high degree of coordination between the tumor-specific CD4 and CD8 T cell responses. Using in-vitroassay, we aim to confirm the presence of these bystander CD4+ TILs specific for cancer-unrelated antigens (HCMV, EBV, Influenza). Overall, our findings could highlight that not all CD4+ TILs are tumor-specific and could suggest measuring CD39 expression as a straightforward way to quantify or isolate tumor-specific T cells, thus opening new diagnostic and therapeutic avenues.
Read more